Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors

Journal of Substance Abuse Treatment

Volumn 30, Issue 4, 2006, Pages 363-373

  Knudsen, Hannah K ^a   Ducharme, Lori J ^a   Roman, Paul M ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Adoption of innovations; Buprenorphine; Health services research

Indexed keywords

BUPRENORPHINE; METHADONE; NALTREXONE; OPIATE;

ACCREDITATION; ARTICLE; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG USE; FOLLOW UP; HEALTH SERVICE; HUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; SUBSTANCE ABUSE;

BUPRENORPHINE; DRUG UTILIZATION; HUMANS; NARCOTIC ANTAGONISTS; PRIVATE SECTOR; PUBLIC SECTOR; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; UNITED STATES;

EID: 33646563473     PISSN: 07405472     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsat.2006.03.013     Document Type: Article

References (50)

1. Amass L., Ling W., Freese T.E., Reiber C., Annon J.J., Cohen A.J., et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. American Journal on Addictions 13 (2004) S42-S46
2. American Methadone Treatment Association. 1998 Methadone maintenance program and patient census in the US (1999), AMTA, New York
3. Bickel W.K., and Amass L. Buprenorphine treatment for opioid dependence: A review. Experimental and Clinical Psychopharmacology 3 (1995) 477-489
4. Center for Substance Abuse Treatment. Evaluation of the buprenorphine waiver program: Study overview. Accessed on July 7, 2005, at (2005). http://buprenorphine.samhsa.gov/Overview_Evaluation_Waiver_Program.pdf
5. Cepeda M.S., Boston R., Farrar J.T., and Strom B.L. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. American Journal of Epidemiology 158 (2003) 280-287
6. Chadderton A. Clinical issues in using buprenorphine in the treatment of opiate dependence. Drug and Alcohol Review 19 (2000) 329-335
7. Chiang C.N., and Hawks R.L. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug and Alcohol Dependence 70 (2003) S29-S47
8. Damanpour F. Organizational innovation: A meta-analysis of effects of determinants and moderators. Academy of Management Journal 34 (1991) 555-590
9. Damanpour F. Organizational complexity and innovation: Developing and testing multiple contingency models. Management Science 42 (1996) 693-716
10. DiPaula B.A., Schwartz R., Montoya I.D., Barrett D., and Tang C. Heroin detoxification with buprenorphine on an inpatient psychiatric unit. Journal of Substance Abuse Treatment 23 (2002) 163-169
11. Fischer G., Gombas W., Eder H., Jagsch R., Peternell A., Stuhlinger G., et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 94 (1999) 1337-1347
12. Fudula P.J., Bridge T.P., Herbert S., Williford W.O., Chiang C.N., Jones K., et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 349 (2003) 949-958
13. Fuller B.E., Rieckmann T., McCarty D., Smith K.W., and Levine H. Adoption of naltrexone to treat alcohol dependence. Journal of Substance Abuse Treatment 28 (2005) 273-280
14. Jaffe J.H., and O'Keeffe C. From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States. Drug and Alcohol Dependence 70 (2003) S3-S11
15. Johnson J.A., and Roman P.M. Predicting closure of private substance abuse treatment facilities. Journal of Behavioral Health Services & Research 29 (2002) 115-125
16. Johnson R.E., Chutuape M.A., Strain E.C., Walsh S.L., Stitzer M.L., and Bigelow G.E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine 343 (2000) 1290-1297
17. Johnson R.E., Jaffe J.H., and Fudula P.J. A controlled trial of buprenorphine treatment for opioid dependence. Journal of the American Medical Association 267 (1992) 2750-2755
18. Johnson R.E., Strain E.C., and Amass L. Buprenorphine: How to use it right. Drug and Alcohol Dependence 70 (2003) S59-S77
19. Kimberly J.R., and Evanisko M.J. Organizational innovation: The influence of individual, organizational, and contextual factors on hospital adoption of technological and administrative innovations. Academy of Management Journal 24 (1981) 689-713
20. Knudsen H.K., Ducharme L.D., Roman P.M., and Link T. Buprenorphine diffusion: The attitudes of substance abuse treatment counselors. Journal of Substance Abuse Treatment 29 (2005) 95-106
21. Knudsen H.K., and Roman P.M. Modeling the use of innovations in private treatment organizations: The role of absorptive capacity. Journal of Substance Abuse Treatment 26 (2004) 353-361
22. Knudsen H.K., Roman P.M., Ducharme L.D., and Johnson A.J. Organizational predictors of pharmacological innovation adoption: The case of disulfiram. Journal of Drug Issues 35 (2005) 553-568
23. Kosten T.R., Schottenfeld R., Ziedonis D., and Falconi J. Buprenorphine versus methadone maintenance for opioid dependence. Journal of Nervous and Mental Diseases 181 (1993) 358-364
24. In: Lamb S., Greenlick M.R., and McCarty D. (Eds). Bridging the gap between practice and research: Forging partnerships with community-based drug and alcohol treatment (1998), National Academy Press, Washington, DC 27-55
25. Ling W., Amass L., Shoptaw S., Annon J.J., Hillhouse M., Babcock D., et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100 (2005) 1090-1100
26. Ling W., and Compton P. Recent advances in the treatment of opiate addiction. Clinical Neuroscience Research 5 (2005) 161-167
27. Ling W., and Smith D. Buprenorphine: Blending practice and research. Journal of Substance Abuse Treatment 23 (2002) 87-92
28. Ling W., Wesson D.R., Charuvastra C., and Klett C.J. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry 53 (1996) 401-407
29. Lintzeris N., Bell J., Bammer G., Jolley D.J., and Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 97 (2002) 1395-1404
30. Mee-Lee D.L., Gartner L., Miller M.M., Shulman G.D., and Wilford B.B. Patient placement criteria for the treatment of substance-related disorders. 2nd ed. (1996), ASAM, Chevy Chase, MD
31. Mello N.K., and Mendelson J.H. Buprenorphine suppresses heroin use by heroin-addicts. Science 207 (1980) 657-659
32. Milne S.H., Blum T.C., and Roman P.M. Quality management in a health care setting: A study of substance abuse treatment centers. Advances in the Management of Organizational Quality 5 (2000) 215-248
33. Pani P.P., Maremmani I., Pirastu R., Tagliamonte A., and Gessa G.L. Buprenorphine: A controlled clinical trial in the treatment of opioid dependence. Drug and Alcohol Dependence 60 (2000) 39-50
34. Peduzzi P., Concato J., Kemper E., Holford T.R., and Feinstein A.R. A simulation study of number of events per variable in logistic regression analysis. Journal of Clinical Epidemiology 49 (1996) 1373-1379
35. Petitjean S., Stohler R., Deglon J.J., Livoti S., Waldvogel D., Uehlinger C., et al. Double-blind placebo trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence 62 (2001) 97-104
36. Rawson R.A., Hasson A.L., Huber A.M., McCann M.J., and Ling W. A 3-year progress report on LAAM in the United States. Addiction 93 (1998) 533-540
37. Rodgers J.H., and Barnett P.G. Two separate tracks? A national multivariate analysis of differences between public and private substance abuse treatment programs. American Journal of Drug and Alcohol Abuse 26 (2000) 429-442
38. Rogers E.M. Diffusion of innovations. 5th ed. (1995), Free Press, New York
39. Roman P.M., and Johnson A.J. Adoption and implementation of new technologies in substance abuse treatment. Journal of Substance Abuse Treatment 22 (2002) 1-8
40. Saxon A.J., and McCarty D. Challenges in the adoption of new pharmacotherapies for addiction to alcohol and other drugs. Pharmacology & Therapeutics 108 (2005) 119-128
41. Schottenfeld R.S., Pakes J.R., Oliveto A., Ziedonis D., and Kosten T.R. Buprenorphine versus methadone maintenance for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry 54 (1997) 713-720
42. Sloboda Z., and Schildhaus S. A discussion of the concept of technology transfer of research-based drug "abuse" prevention and treatment interventions. Substance Use & Misuse 37 (2002) 1079-1087
43. In: Strain E. (Ed). Use of buprenorphine in the pharmacologic management of opioid dependence: A curriculum for physicians (2001). Retrieved on December 9, 2003, from www.buprenorphine.samhsa.gov/buprenorphine_curriculum.pdf
44. Strain E.C., Stitzer M.L., Liebson I.A., and Bigelow G.E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry 151 (1994) 1024-1030
45. Substance Abuse and Mental Health Services Administration. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction (Treatment Improvement Protocol #40) (2004), SAMHSA, Rockville, MD
46. Uehlinger C., Deglon J., Livoti S., Petitjean S., Waldvogel D., and Ladewig D. Comparison of buprenorphine and methadone in the treatment of opioid dependence: Swiss multicentre study. European Addiction Research 4 Suppl 1 (1998) 13-18
47. Walsh S.L., and Eissenberg T. The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic. Drug and Alcohol Dependence 70 (2003) S13-S27
48. West J.C., Kosten T.R., Wilk J., Svikis D., Triffleman E., Rae D.S., et al. Challenges to increasing access to buprenorphine treatment for opiate addiction. American Journal on Addictions 13 (2004) S8-S16
49. White W.L. Slaying the dragon: The history of addiction treatment and recovery in America (1998), Chestnut Health Systems, Bloomington, IL
50. Yahr H.T. A national comparison of public- and private-sector alcoholism treatment delivery system characteristics. Journal of Studies on Alcohol 49 (1986) 233-239